Sign in
4

Changes in Ownership

Celldex Therapeutics, Inc. Filed Acc 0001179110-21-011251

SVP and CFO sold 9,500 shares at $42.00 ($399,000)

  • SVP and CFO acquired 7,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Martin Samuel Bates SVP and CFO 2021-12-23 Option exercise +3,250 $9.02 $29,304 30,128 D
Martin Samuel Bates SVP and CFO 2021-12-23 Option exercise +3,750 $2.78 $10,425 33,878 D
Martin Samuel Bates SVP and CFO 2021-12-23 Sale −9,500 $42.00 $399,000 24,378 D
Derivatives
Martin Samuel Bates SVP and CFO 2021-12-23 Option exercise · Incentive Stock Option (Right to Buy) −3,250 9,530 D
Martin Samuel Bates SVP and CFO 2021-12-23 Option exercise · Incentive Stock Option (Right to Buy) −3,750 24,421 D
Open-market sales · 9,500 sh · avg $42.00 · $399,000
Loading xslF345X03/edgar.xml…